Interestingly, the narrow range of function of hERG channels enables hyperstimulation via hERG channel agonists as a viable method to irreversibly inhibit the proliferation of tumour cells that are ectopically expressing the channel, while simultaneously minimising cardiotoxic risk [30, 31]. Here, KCNH2 is linked to neoplasm.